Neuropsychiatric symptoms (NPS) are among the most common manifestations of cognitive impairment, yet their heterogeneity complicates understanding of how they relate to Alzheimerâs disease (AD) pathology. While individual NPS have been linked to AD... Uncover the latest and most…
A large international team of scientists is shedding new light on a long-standing puzzle in mental health: why many people are diagnosed with more than one psychiatric disorder over their lifetime. In research published December 10 in the journal Nature, the…
Scientists have identified a brain signal that may help explain why schizophrenia produces such a wide variety of symptoms, including difficulties with perception, movement, and speech. The discovery suggests that problems that appear unrelated could actually stem from a shared…
In this episode of Beyond Blue, Yale psychiatrist Deepak D’Souza explains the mental health risks posed by today’s legal, readily available cannabis products. Plus, when we should think twice about the answers from AI chatbots; the quiet evolution of salamanders;…
Newly developed “apallial” mice are forgetful, have a cautious gait, have notable behavioral variation from one mouse to the next, and are missing 98% of their cerebral cortex and hippocampus. The sprawling open space in their tiny skulls is intentional. Neuroscientist…
Recipes Beverages and Smoothie Recipes Food Features What Is A Low FODMAP Serving Size? Meal PlannerLow FODMAP Meal Planner! By Glory Oj, on October 28, 2026 This post may contain affiliate links. Please see our disclosure policy for details. In a study…
MapLight Therapeutics gets a Hold as mixed-phase 2 schizophrenia data temper outlook. Click here to read my most recent analysis of MPLT stock. - I initiate MapLight Therapeutics with a "Hold" rating due to mixed phase 2 data for ML-007C-MA in Schizophrenia. - MapLight's…
This is all the problem with the field of metabolic psychiatry as a whole. This is not to say that metabolism is not important to mental and neurological health. It is. But that is not the same thing as metabolism…
Adults with bipolar disorder and chronic kidney disease who used GLP-1 medicines had lower observed rates of dialysis or kidney transplantation than comparison groups, a study of health records found. The results are encouraging but do not prove the medicines…
Schizophrenia affects millions of people worldwide, yet its biological origins are poorly defined. Genetics and disruptions to brain development are known to increase risk, but researchers still do not fully understand the molecular and cellular processes that produce the disorder's…
Serious mental illness: bipolar disorder, schizophrenia and psychosis, new drugs, treatment and care.
An article joins this feed when it matches these terms. Each one is also a search of its own.